Literature DB >> 26869584

Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.

Sebastian Giebel1, Myriam Labopin2, Adalberto Ibatici3, Paul Browne4, Tomasz Czerw5, Gerard Socie6, Ali Unal7, Slawomira Kyrcz-Krzemien8, Andrea Bacigalupo3, Hakan Goker9, Mike Potter10, Caroline L Furness10, Grant McQuaker11, Dietrich Beelen12, Noel Milpied13, Antonio Campos14, Charles Craddock15, Arnon Nagler16, Mohamad Mohty2.   

Abstract

PURPOSE: From a global perspective, the rates of allogeneic hematopoietic cell transplantation (alloHCT) are closely related to the economic status of a country. However, a potential association with outcome has not yet been documented. The goal of this study was to evaluate effects of health care expenditure (HCE), Human Development Index (HDI), team density, and center experience on nonrelapse mortality (NRM) after HLA-matched sibling alloHCT for adults with acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: A total of 983 patients treated with myeloablative alloHCT between 2004 and 2008 in 24 European countries were included.
RESULTS: In a univariate analysis, the probability of day 100 NRM was increased for countries with lower current HCE (8% vs. 3%; p = .06), countries with lower HDI (8% vs. 3%; p = .02), and centers with less experience (8% vs. 5%; p = .04). In addition, the overall NRM was increased for countries with lower current HCE (21% vs. 17%; p = .09) and HDI (21% vs. 16%; p = .03) and for centers with lower activity (21% vs. 16%; p = .07). In a multivariate analysis, the strongest predictive model for day 100 NRM included current HCE greater than the median (hazard ratio [HR], 0.39; p = .002). The overall NRM was mostly predicted by HDI greater than the median (HR, 0.65; p = .01). Both lower current HCE and HDI were associated with decreased probability of overall survival.
CONCLUSION: Both macroeconomic factors and the socioeconomic status of a country strongly influence NRM after alloHCT for adults with ALL. Our findings should be considered when clinical studies in the field of alloHCT are interpreted. ©AlphaMed Press.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Health care expenditure; Hematopoietic cell transplantation; Human development index; Non-relapse mortality

Mesh:

Year:  2016        PMID: 26869584      PMCID: PMC4786353          DOI: 10.1634/theoncologist.2015-0314

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  19 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation.

Authors:  K Matsuo; N Hamajima; Y Morishima; M Harada
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

3.  Hematopoietic stem cell transplantation: a global perspective.

Authors:  Alois Gratwohl; Helen Baldomero; Mahmoud Aljurf; Marcelo C Pasquini; Luis Fernando Bouzas; Ayami Yoshimi; Jeff Szer; Jeff Lipton; Alvin Schwendener; Michael Gratwohl; Karl Frauendorfer; Dietger Niederwieser; Mary Horowitz; Yoshihisa Kodera
Journal:  JAMA       Date:  2010-04-28       Impact factor: 56.272

4.  Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers?

Authors:  M M Horowitz; D Przepiorka; R E Champlin; R P Gale; A Gratwohl; R H Herzig; H G Prentice; A A Rimm; O Ringdén; M M Bortin
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

Review 5.  The EBMT risk score.

Authors:  A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2011-06-06       Impact factor: 5.483

6.  Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  F Frassoni; M Labopin; R Powles; J Y Mary; W Arcese; A Bacigalupo; D Bunjes; E Gluckman; T Ruutu; U W Schaefer; J Sierra; J P Vernant; R Willemze; T de Witte; N C Gorin
Journal:  Lancet       Date:  2000-04-22       Impact factor: 79.321

7.  Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia.

Authors:  M van Agthoven; M T Groot; L F Verdonck; B Löwenberg; A V M B Schattenberg; M Oudshoorn; A Hagenbeek; J J Cornelissen; C A Uyl-de Groot; R Willemze
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483

8.  Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.

Authors:  Navneet S Majhail; Jaya M Mothukuri; Claudio G Brunstein; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2009-03-09       Impact factor: 5.742

9.  Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.

Authors:  Alois Gratwohl; Ronald Brand; Dietger Niederwieser; Helen Baldomero; Christian Chabannon; Jan Cornelissen; Theo de Witte; Per Ljungman; Fiona McDonald; Eoin McGrath; Jakob Passweg; Christina Peters; Vanderson Rocha; Ineke Slaper-Cortenbach; Anna Sureda; Andre Tichelli; Jane Apperley
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

10.  Cost of hematopoietic stem cell transplantation in India.

Authors:  Sanjeev Kumar Sharma; Dharma Choudhary; Nitin Gupta; Mayank Dhamija; Vipin Khandelwal; Gaurav Kharya; Anil Handoo; Rasika Setia; Arpita Arora
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-07-01       Impact factor: 2.576

View more
  4 in total

1.  Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases.

Authors:  John A Snowden; Manuela Badoglio; Myriam Labopin; Sebastian Giebel; Eoin McGrath; Zora Marjanovic; Joachim Burman; John Moore; Montserrat Rovira; Nico M Wulffraat; Majid Kazmi; Raffaella Greco; Emilian Snarski; Tomas Kozak; Kirill Kirgizov; Tobias Alexander; Peter Bader; Riccardo Saccardi; Dominique Farge
Journal:  Blood Adv       Date:  2017-12-20

2.  Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.

Authors:  William A Wood; Ruta Brazauskas; Zhen-Huan Hu; Hisham Abdel-Azim; Ibrahim A Ahmed; Mahmoud Aljurf; Sherif Badawy; Amer Beitinjaneh; Biju George; David Buchbinder; Jan Cerny; Laurence Dedeken; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Usama Gergis; David Gomez Almaguer; Ashish Gupta; Gregory Hale; Shahrukh K Hashmi; Yoshihiro Inamoto; Rammurti T Kamble; Kehinde Adekola; Tamila Kindwall-Keller; Jennifer Knight; Lalit Kumar; Yachiyo Kuwatsuka; Jason Law; Hillard M Lazarus; Charles LeMaistre; Richard F Olsson; Michael A Pulsipher; Bipin N Savani; Kirk R Schultz; Ayman A Saad; Matthew Seftel; Sachiko Seo; Thomas C Shea; Amir Steinberg; Keith Sullivan; David Szwajcer; Baldeep Wirk; Jean Yared; Agnes Yong; Jignesh Dalal; Theresa Hahn; Nandita Khera; Carmem Bonfim; Yoshiko Atsuta; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-19       Impact factor: 5.742

3.  Increasing access to allogeneic hematopoietic cell transplant: an international perspective.

Authors:  Vanderson Rocha; Giancarlo Fatobene; Dietger Niederwieser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT.

Authors:  Andrzej Frankiewicz; Christophe Peczynski; Sebastian Giebel; Alenca Harrington; Gerard Socié; Dietger Niederwieser; Christoph Scheid; Martin Bornhäuser; Nicolaus Kröger; Ahmet Elmaagacli; Boris Afanasyev; Peter Dreger; Claudia Rössig; Didier Blaise; Christian Kratz; Ibrahim Yakoub-Agha; Bernhard Kremens; Charlotte Marie Niemeyer; Gerald Wulf; Igor Blau; Olaf Penack; Hildegard Greinix; Grzegorz W Basak
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.